New digital health partnerships, breakthroughs in the US for two local pharmas, and an award for a piece of Aussie software. It’s all happening.
Health tech start-up Telecare has gone live with its virtual inpatient model of care at Corryong Health in Victoria.
Codesigned with Corryong Health’s management, the model includes a staff GP medical officer and Telecare FRACP physicians conducting weekly virtual whiteboard rounds at patients’ bedsides, bringing together local and virtual clinical expertise to deliver better outcomes for patients.
The team at Telecare says the program is already having a positive clinical impact.
“By combining local knowledge with our virtual care platform, we’re able to provide high-quality, patient-centred care to rural communities that have historically faced challenges in accessing healthcare services,” said the Telecare team on LinkedIn.
The model of care is endorsed by the Hume Health Services Partnership, which was established in July 2021 with the aim of enabling the public health services across the region to work in collaboration on a number of strategic system priorities determined by the Victorian government and local priorities.
Gong for TrakCare
Aussie data tech provider InterSystems has been presented with a gong at the Best in KLAS Awards, based on customer input and satisfaction.
InterSystems’ TrakCare EMR system was recognised as the top acute care electronic health record in Asia and Oceania.
KLAS Research, which evaluates IT systems in the healthcare industry, placed InterSystems TrakCare in the top rank of the Acute Care EHR (Global) (Asia/Oceania) category.
The category covers electronic health record software products used outside the US that provide core inpatient functionality, including a clinical data repository, order entry, ePrescribing, results reporting, and/or clinician charting and documentation. The Asia/Oceania region includes countries where InterSystems has a major presence, including Australia, China, Indonesia, Japan, New Zealand, Singapore and Thailand.
“This Best in KLAS award reflects high customer satisfaction ratings for InterSystems TrakCare among our customers, including leading private hospitals and public healthcare providers in the region,” said Luciano Brustia, Regional Managing Director, Asia Pacific at InterSystems.
“TrakCare is a flexible and powerful EMR system that we are constantly innovating to drive care transformation, and we are proud to see that reflected in the latest customer input to KLAS Research.”
Clarity’s prostate cancer treatment advances
ASX-listed Clarity Pharmaceuticals has been granted a fast-track designation by the US Food and Drug Administration for its 64 Cu-SAR-bisPSMA treatment for metastatic castration-resistant prostate cancer in patients who have been previously treated with androgen receptor pathway inhibition.
This milestone builds on Clarity’s earlier receipt of two FTDs for the diagnostic 64 Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy, as well as patients with biochemical recurrence of prostate cancer following definitive therapy.
The FTDs will enable Clarity to accelerate the development of its comprehensive program with the optimised SAR-bisPSMA agent to be used in patients with prostate cancer throughout the management of their cancer, from initial to late-stage disease, with an opportunity to completely change the entire treatment landscape for the large prostate cancer market.
“Receiving three FTDs for the one molecule, SAR-bisPSMA, within the last six months is an incredible achievement for Clarity, highlighting how impressive our science and development are, the significance of the diagnostic and therapeutic data so far, and the high unmet need for better therapies and diagnostics in prostate cancer,” said Clarity’s executive chair Dr Alan Taylor.
Icon commits to another charming five years
Australian cancer care provider Icon Group has extended its relationship with Magentus, signing another five-year contract for the continued use of the Charm oncology information management system.
The initial deal was inked in 2016 and has seen Charm implemented in all Icon sites across the country.
By digitising manual processes, the system supports adherence to best practice clinical guidelines and improves clinical safety by minimising transcription errors and enabling real-time adjustments to treatment plans based on patient needs.
Related
FDA fast track for Neuren PTHS drug
Melbourne-based pharma Neuren has received a fast-track designation from the US Food and Drug Administration as a treatment candidate for Pitt Hopkins syndrome, NNZ-2591.
Currently there are no treatments approved to treat PTHS, a neurodevelopmental condition caused by the loss of one copy or a mutation of the TCF4 gene on chromosome 18. The incidence of PTHS has been estimated at between one in 34,000 and one in 41,000 people. It causes a range of developmental delays with moderate-to-severe intellectual disability and behavioural differences, hyperventilation and/or breath-holding while awake, seizures, gastrointestinal issues, lack of speech, sleep disturbance, stereotypic hand movements and distinctive facial features.
In Neuren’s Phase II clinical trial of NNZ-2591 in children with PTHS, 82% of participants showed improvement, including communication, social interaction, cognition and motor abilities.
NNZ-2591 is also in development for treatment of Phelan-McDermid syndrome and Angelman syndrome.
ParagonCare and Coreline Soft
ASX-listed health tech ParagonCare and Coreline Soft, an AI-powered medical imaging software firm, have partnered up to deliver lung cancer screening solutions into Australian hospitals.
The AVIEW product line offers 3D CT image analysis solutions. AVIEW LCS Plus, which can simultaneously screen for lung cancer, emphysema and coronary artery calcification, supports large-scale data analysis and precise nodule detection. It reduces diagnostic variability among medical professionals and is currently supplied to lung cancer screening programs in South Korea, Europe, Germany, Italy and more.